In this issue:
Predicting fibrosis regression after suppression of viral replication
High HBV reactivation rate after allogeneic HSCT
Molecular mechanisms driving HCC in HCV
Test for the TLL1 gene even after HCV clearance?
Restoring innate immune responsiveness in HBV
Persistence of Tregs after HCV “cure” may lead to liver disease
Test for NS5A RASs prior to NS5A inhibitor therapy in HCV?
The importance of autotaxin in HCV replication
Ledipasvir/sofosbuvir: high efficacy in genotype 2 HCV
Elbasvir/grazoprevir and compensated cirrhosis
Please login below to download this issue (PDF)